Skip to main content
Terug
Watch Compare

BioRestorative Therapies, Inc.

Datakwaliteit: 100%
BRTX
Nasdaq Services Health Services
€ 0,25
▼ € 0,01 (-4,17%)
Marktkapitalisatie: 6,27 M
Prijs
€ 0,25
Marktkapitalisatie
6,27 M
Dagbereik
€ 0,25 — € 0,26
52-Weeksbereik
€ 0,19 — € 2,05
Volume
1.000.070
Openen € 0,26
50D / 200D Gem.
€ 0,47
47,79% below
50D / 200D Gem.
€ 1,19
79,27% below

Quick Summary

Belangrijkste Punten

Revenue grew 67,22% annually over 5 years — strong growth
Negative free cash flow of -10,91 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 77,52%
Capital intensive — 32,27% of revenue goes to capex

Groei

Revenue Growth (5Y)
67,22%
Boven sectorgemiddelde (4,21%)
Revenue (1Y)-10,30%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-403,90%
Onder sectorgemiddelde (-15,74%)
ROIC-350,56%
Net Margin-3959,40%
Op. Margin-4350,05%

Veiligheid

Debt / Equity
N/A
Current Ratio1,37
Interest Coverage-58,78

Waardering

PE (TTM)
-0,44
Boven sectorgemiddelde (-1,17)
P/B Ratio2,84
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Services sector mediaan (502 peers)
Metriek Aandeel Sector Mediaan
P/E -0,4 -1,2
P/B 2,8 1,4
ROE % -403,9 -15,7
Net Margin % -3959,4 -18,3
Rev Growth 5Y % 67,2 4,2
D/E — 0,4

All Fundamental Metrics
Growth
Revenue Growth (1Y) -10,30% Revenue Growth (3Y) 57,07%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 67,22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 359.700,0 Net Income (TTM) -14,24 M
ROE -403,90% ROA -201,17%
Gross Margin 93,37% Operating Margin -4350,05%
Net Margin -3959,40% Free Cash Flow (TTM) -10,91 M
ROIC -350,56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,37
Interest Coverage -58,78 Asset Turnover 0,05
Working Capital 1,27 M Tangible Book Value 1,65 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,44 Forward P/E N/A
P/B Ratio 2,84 P/S Ratio 17,43
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -173,92%
Market Cap 6,27 M Enterprise Value 5,67 M
Per Share
EPS (Diluted TTM) -1,58 Revenue / Share 0,01
FCF / Share -0,43 OCF / Share -0,42
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 32,27% FCF Conversion 76,57%
SBC-Adj. FCF -14,07 M Growth Momentum -77,52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 359.700,0 401.000,0 145.800,0 119.800,0 46.000,0
Net Income -14,24 M -8,98 M -14,42 M -18,49 M -44,30 M
EPS (Diluted) -1,58 -1,16 -3,42 — —
Gross Profit 335.856,0 372.928,0 — — —
Operating Income -15,65 M -11,56 M -15,22 M -18,97 M -26,31 M
EBITDA — — — — —
R&D Expenses 10,09 M 5,35 M 4,03 M 3,51 M 729.058,0
SG&A Expenses — — — — —
D&A 209.985,0 189.056,0 165.735,0 120.545,0 89.108,0
Interest Expense 266.207,0 616.077,0 552.293,0 11.650,0 —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4,08 M 12,28 M 12,61 M 16,43 M 22,45 M
Total Liabilities — 3,75 M 1,06 M 602.619,0 856.497,0
Shareholders' Equity 356.744,0 8,53 M 11,55 M 15,83 M 21,60 M
Total Debt — — — — 250.000,0
Cash & Equivalents 1,51 M 547.890,0 884.377,0 1,68 M —
Current Assets 3,14 M 11,14 M 11,39 M 15,13 M 21,47 M
Current Liabilities 3,72 M 3,75 M 1,06 M 440.302,0 363.822,0